Johnson & Johnson (NYSE:JNJ) Shares Purchased by Segment Wealth Management LLC

Segment Wealth Management LLC lifted its stake in Johnson & Johnson (NYSE:JNJ) by 8.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,357 shares of the company’s stock after purchasing an additional 270 shares during the quarter. Segment Wealth Management LLC’s holdings in Johnson & Johnson were worth $485,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Legal Advantage Investments Inc. grew its position in Johnson & Johnson by 62.7% in the fourth quarter. Legal Advantage Investments Inc. now owns 2,596 shares of the company’s stock worth $375,000 after acquiring an additional 1,000 shares during the period. Hamlin Capital Management LLC grew its position in Johnson & Johnson by 9.6% in the fourth quarter. Hamlin Capital Management LLC now owns 1,076,740 shares of the company’s stock worth $155,718,000 after acquiring an additional 94,147 shares during the period. Sugar Maple Asset Management LLC purchased a new position in Johnson & Johnson in the fourth quarter worth approximately $60,000. Mitchell & Pahl Private Wealth LLC grew its position in Johnson & Johnson by 4.2% in the fourth quarter. Mitchell & Pahl Private Wealth LLC now owns 18,174 shares of the company’s stock worth $2,628,000 after acquiring an additional 739 shares during the period. Finally, Ballentine Partners LLC boosted its position in shares of Johnson & Johnson by 2.6% during the fourth quarter. Ballentine Partners LLC now owns 57,853 shares of the company’s stock worth $8,367,000 after buying an additional 1,461 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction on Thursday, December 12th. The shares were bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.16% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research analysts have recently commented on JNJ shares. Stifel Nicolaus lowered their price target on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research report on Thursday. Citigroup lowered their price target on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Raymond James lowered their price target on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday. StockNews.com lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Friday, January 17th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 16th. Nine investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $170.06.

Johnson & Johnson Stock Up 0.9 %

JNJ opened at $146.58 on Friday. The business’s 50-day simple moving average is $148.10 and its 200-day simple moving average is $156.05. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The stock has a market capitalization of $352.91 billion, a P/E ratio of 21.21, a price-to-earnings-growth ratio of 2.52 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22,438,500 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.29 EPS. Analysts anticipate that Johnson & Johnson will post 9.95 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.38%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 71.78%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.